Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives

NHS England

This public procurement record has 5 releases in its history.

Award

07 Apr 2026 at 16:16

UK7 - Contract Details Notice
Award

26 Feb 2026 at 15:59

UK6 - Contract Award Notice
TenderUpdate

28 Jan 2026 at 12:58

UK4 - Tender Notice
Tender

22 Dec 2025 at 16:55

UK4 - Tender Notice
Planning

17 Oct 2025 at 16:37

UK2 - Preliminary Market Engagement Notice
Summary of the contracting process

NHS England has completed an open procurement process for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the implementation of Hepatitis C elimination initiatives. This procurement, which falls under the healthcare industry category, involves a framework agreement with the option to extend by two additional years beyond the initial period from April 2026 to March 2028. The open procedure allowed for tenders from multiple UK regions and involved major suppliers such as Abbvie Ltd and Gilead Sciences Limited. The contract, awarded in early April 2026, signifies a significant investment in pharmaceutical products valued at £160 million, with the potential to reach £192 million gross.

This framework offers substantial business growth opportunities, particularly for large-scale pharmaceutical companies equipped to provide innovative Hepatitis C treatment solutions. The open procedure facilitated a competitive tendering process, advantageous for suppliers with robust capabilities in pharmaceutical manufacturing and distribution. Companies with experience in handling large-scale government contracts and those aiming to enhance their market position within the NHS supply chain will find this contract particularly beneficial. SMEs with niche expertise in antiviral treatments may also find opportunities for collaboration or subcontracting within the framework's extensive scope.

How relevant is this notice?

Notice Information

Notice Title

NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives

Notice Description

Project title: NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives commencing 1st April 2026 Offer reference number: CM/TNS/25/5737 Period of framework: 1 April 2026 to 31 March 2028 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot Information

Lot 1

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Renewal: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Planning Information

NHS England is seeking to engage with suppliers of Hepatitis C treatments. Interested suppliers will be invited to a virtual PME meeting to be held w/c 3rd or 10th November 2025. The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, proposed framework period, tender structure, and KPl's. Please contact liz.fleetwood1@nhs.net to register your interest in tendering for this framework.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-05cf3b
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/031606-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£160,000,000 £100M-£1B
Lots Value
£160,000,000 £100M-£1B
Awards Value
£160,000,000 £100M-£1B
Contracts Value
£160,000,000 £100M-£1B

Notice Dates

Publication Date
7 Apr 20264 months ago
Submission Deadline
6 Feb 2026Expired
Future Notice Date
1 Dec 2025Expired
Award Date
25 Feb 20266 months ago
Contract Period
1 Apr 2026 - 31 Mar 2028 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
2
Supplier Names

Abbvie Ltd

Gilead Sciences Limited

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...